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The adaptive immune system protects organisms from harmful environmental insults. In
parallel, regulatory mechanisms control immune responses in order to assure preservation
of organ integrity. Yet, molecules involved in the control of T-cell responses in peripheral
tissues are poorly characterized. Here, we investigated the function of Dickkopf-3 in the
modulation of local T-cell reactivity. Dkk3 is a secreted, mainly tissue-derived protein with
highest expression in organs considered as immune-privileged such as the eye, embryo,
placenta, and brain. While T-cell development and activation status in naïve Dkk3-deficient
mice was comparable to littermate controls, we found that Dkk3 contributes to the immuno-
suppressive microenvironment that protects transplanted, class-I mismatched embryoid
bodies from T-cell-mediated rejection. Moreover, genetic deletion or antibody-mediated
neutralization of Dkk3 led to an exacerbated experimental autoimmune encephalomyelitis
(EAE). This phenotype was accompanied by a change of T-cell polarization displayed by
an increase of IFNγ-producing T cells within the central nervous system. In the wild-
type situation, Dkk3 expression in the brain was up-regulated during the course of EAE
in an IFNγ-dependent manner. In turn, Dkk3 decreased IFNγ activity and served as part
of a negative feedback mechanism. Thus, our findings suggest that Dkk3 functions as a
tissue-derived modulator of local CD4+ and CD8+ T-cell responses.
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INTRODUCTION
Adaptive immune responses in vital organs have to be precisely
coordinated in order to assure proper pathogen clearance and at
the same time, to prevent extended immune-mediated inflamma-
tion that might impair their function. In particular, this is essential
for tissues with limited regenerative capacity such as the central
nervous system (CNS), the eye, and the pregnant uterus. In these
organs, extensive inflammation is prevented locally by mecha-
nisms such as immune deviation away from destructive immune
responses or by active suppression of inflammation.
Besides the self-regulating capacity of the immune system,
tissue-resident cells also play an important role in the surveillance
of T-cell responses by production of immunosuppressive mole-
cules. For example, programed death-ligand 1 (PD-L1), FasL, and
indoleamine 2,3-dioxygenase (IDO) have already been reported
to be expressed in peripheral tissues associated with an immuno-
suppressive micromilieu. PD-L1, a mediator of peripheral T-cell
tolerance, is expressed by endothelial cells in the heart, muscle cells,
β-cells in the pancreas, and glial cells in the inflamed brain (1–5).
Via interaction with its receptor, PD-L1 induces co-inhibitory sig-
nals in activated T cells and promotes T-cell apoptosis, anergy, and
functional exhaustion (6, 7). Furthermore, FasL, which induces
apoptosis of activated T cells, is expressed by neurons, astrocytes,
oligodendrocytes, microglia (8), the stroma cells of the retina (9),
and on fetal cytotrophoblasts and maternal decidual cells of the
placenta (10). Moreover, trophoblasts were shown to produce the
enzyme IDO, which catabolizes the amino acid tryptophan, nec-
essary for T-cell survival. The presence of IDO in the trophoblast
results in inactivation and apoptosis of T lymphocytes through
tryptophan deprivation (11). IDO is also produced by several cell
types in the eye (12, 13) and in the brain (14).
Dickkopf-3 (Dkk3) belongs to an evolutionary conserved small
gene family, which encodes five secreted glycoproteins, Dkk1-4,
and Dkkl1 that share two conserved cysteine-rich domains (15).
While Dkk1, 2, and 4 have been shown to induce head forma-
tion during embryogenesis via modulation of the Wnt-pathway,
Dkk3 is not involved in head development (15, 16). There is
though, increasing evidence that it may also interfere with Wnt
signaling (17–19). Expression studies revealed highest Dkk3 lev-
els in tissues such as brain, spinal cord, eye, embryo, ovary, and
uterus (15, 17).
In a T-cell receptor (TCR)–MHC class-I double transgenic
mouse system, we previously identified Dkk3 as a modulator of
CD8 T-cell responses. Under these conditions, the induction of
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antigen-specific, peripheral CD8 T-cell tolerance was dependent
on the presence of Dkk3 (20). However, the immunological func-
tion of Dickkopf-3 in the physiological situation of a polyclonal
T-cell repertoire still remains unclear. Here, we show that Dkk3
functions as a tissue-derived modulator of T-cell responses that
locally controls activation and differentiation of T lymphocytes.
Our findings provide strong evidence that Dkk3 contributes to the
immunoregulatory properties of the tissue microenvironment and
therefore may provide a valuable target for immune intervention
in autoimmunity, transplantation, and inflammatory disease.
MATERIALS AND METHODS
MICE
C57BL/6N and IFNγR1−/− were obtained from Jackson Laborato-
ries. Dkk3−/− mice were provided by Niehrs (21) and backcrossed
on C57BL/6N background for more than 10 times. All mice were
kept under specific pathogen-free conditions (SPF) at the ani-
mal facility of the German Cancer Research Center and used at
the age of 8–14 weeks. Animal care was in concordance with the
instructions of the regulating authorities.
FLOW CYTOMETRY
Surface-antigen staining was performed according to stan-
dard protocols using the following antibodies: CD3-PerCpCy5.5
(BioLegend), CD4-PB (BioLegend), CD8-APC-Cy7 (eBioscience),
CD25-PE (BD Bioscience), CD44-PeCy7 (BioLegend), CD62L-
APC (eBioscience), anti-TCR-Vβ antibodies (BD Bioscience).
For intracellular cytokine staining, 1× 106 lymphocytes were re-
stimulated with 50µg/ml myelin oligodendrocyte-derived gly-
coprotein (MOG)33–55 peptide in the presence of Golgi Plug
(BD Bioscience) for 6 h. The staining was performed with
Cytofix/Cytoperm reagents (BD Bioscience) according to the man-
ufacturer’s protocol. The following antibodies were used: IL-17-
APC (BD Biosciences), GM-CSF-APC (BD Biosciences), IFNγ-
APC (BD Biosciences). Intracellular transcription factor staining
was performed using a FoxP3 staining buffer set (eBioscience) and
a FoxP3-APC antibody (eBioscience) according to the manufac-
turer’s protocol. Flow cytometry was performed on a FACSCanto
(BD Bioscience) with FACS Diva software (BD Bioscience) and
analyzed with FlowJo 9.6 (Treestar).
EMBRYOID BODY GENERATION AND TRANSPLANTATION
Embryoid bodies (EBs) were generated for transplantation as
described previously (22). In brief, ES cell lines were cultured
on mitotically inactivated embryonic fibroblasts. Before differ-
entiation, ES cells were passaged on gelatinized flasks in the
presence of leukemia-inhibitory factor to maintain their pluripo-
tency. After two passages in the absence of fibroblasts, single-cell
suspensions were plated onto dishes of bacteriological plastic
to generate EB ready for transplantation at day 14 of cul-
ture. Transplantation of EB was carried out as described pre-
viously (22). Briefly, two to four EB were grafted under the
kidney capsule, and groups of mice were killed for analysis
at specified time points. Acceptance of the grafted tissues was
defined as an increase in diameter to >5 mm, vascularization,
and the lack of leukocyte infiltrate and tissue damage, revealed
by histology.
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
Experimental autoimmune encephalomyelitis (EAE) was induced
by injecting 200µg MOG33–55 peptide emulsified in 100µl com-
plete Freund’s adjuvant containing 200µg Mycobacterium tubercu-
losis (Thomas Geyer) s.c. At days 0 and 2 after immunization, each
mouse received 200 ng pertussis toxin i.p. (Merck Biosciences).
Clinical symptoms were scored as follows: 0, normal; 1, limp tail
or hind limb weakness; 2, limp tail and hind limb weakness; 3, par-
tial hind limp paralysis; 4, complete hind limb paralysis; 5, dead
or moribund, killed by investigator.
IMMUNOHISTOLOGY
Mice were heart-perfused and CNS tissues were fixed with
phosphate-buffered 4% formaldehyde. Three-micrometer paraf-
fin sections were de-paraffinized and rehydrated, before staining.
For immunohistochemistry, the TSA-Indirect Kit was used (NEN
Life Science Products). For fluorescence microscopy, sections were
stained with anti-Dkk3, anti-NeuN (Millipore), or anti-GFAP
(Millipore) antibodies. As a standard negative control, anti-Dkk3
was substituted by equal amounts of normal mouse IgG (Santa
Cruz Biotechnology). Pictures were generated on a cell observer
microscope (Zeiss).
ISOLATION OF LYMPHOCYTES FROM CNS
Experimental autoimmune encephalomyelitis-diseased Dkk3−/−
and wild-type (WT) mice were heart-perfused with PBS. Brain
and spinal cord was removed and minced in ice-cold PBS with
7% FCS. Remaining pieces were digested in 2.5 mg/ml collagenase
D (Roche) and 1 mg/ml DNAse I (Roche) in PBS for 30 min at
37°C and three times mashed through a 40-µm nylon sieve (Fal-
con). Finally, lymphocytes were isolated by a Percoll gradient (GE
Healthcare).
qRT-PCR
Total RNA was extracted from skin using a FastPrep tissue homog-
enizer (ThermoScan) and the RNeasy kit (Qiagen). Purified RNA
was reverse transcribed using the SuperScript II kit (Invitrogen).
Quantitative real-time PCR was performed on a 7500 RT-PCR
System (Applied Biosystems) using Absolute qPCR SYBR Green
ROX Mix (Thermo Scientific) with a final primer concentration
of 200 nM. Primer sequences: Actb primer: 5′-TGACAGGATGC
AGAAGGAGATTA-3′/5′-AGCCACCGATCCACACAGA-3′; Dkk3
primer: 5′-TCCCATTGCCACCTTTGG-3′/5′-CCAGTTCTCCA
GCTTCAAGTACAC-3′; Cxcl9 primer: 5′-CTTCGAGGAACCC
TAGTGATAAGG-3′/5′-CCTCGGCTGGTGCTGATG-3′; Cxcl10
primer: 5′-GACGGTCCGCTGCAACTG-3′/5′-CCCTATGGCCC
TCATTCTCA-3′; Ccl2 primer: 5′-AGCAGGTGTCCCAAAGAAG
CT-3′/5′-GGGTCAGCACAGACCTCTCTCT-3′; Ccl5 primer: 5′-
CTGCTTGCTCTAGTCCA-3′/5′-ATGCTGATTTCTTGGGTTT-
3′; Gbp2 primer: 5′-GATGAACAAGCTAGCTGGGAAGAG-3′/5′-
CCTTGGTGTGAGACTGCACAGT-3′. Data were calculated rel-
ative to the housekeeping gene Actb by using the 2−∆∆Ct
method.
ENZYME-LINKED IMMUNOSORBENT ASSAY
A flexible assay plate (BD Biosciences) was coated with anti-
Dkk3-4.22 antibody (1µg/ml). Tissues were homogenized in Pro-
teoJET mammalian cell lysis reagent (Fermentas) supplemented
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with Complete, EDTA-free, protease inhibitor cocktail (Roche).
Biotinylated goat anti-mouse Dkk3 antibody (R&D Systems, Min-
neapolis, MN, USA) at a final concentration of 1µg/ml was used as
detection antibody. Streptavidin-peroxidase (Jackson ImmunoRe-
search) diluted in PBS-Tween was added for 30 min at room
temperature. After washing, orthophenylene diamine substrate at
a concentration of 1 mg/ml in 100 mM sodium hydrogen phos-
phate buffer containing 0.03% peroxide was applied. The reaction
was stopped with 2 M sulfuric acid. Optical densities were analyzed
with a Viktor 2 photometer (Perkin Elmer) at 490 nm.
DORSAL ROOT GANGLIA
L2–L6 dorsal route ganglia (DRG) neurons isolation and cultured
was performed as described (23). DRGs were excised and roots
and membranes were removed and placed in sterile calcium- and
magnesium-free PBS. Ganglia were collected and resuspended in
DMEM/F12 (1:1) containing 10% horse serum, 2% penicillin–
streptomycin solution,1% l-glutamine,and 0.8%d-glucose (w/v).
0.1% collagenase was added and the tissue incubated at 37°C
for 45 min. The tissue was incubated for a further 45 min in
growth medium containing 0.05% trypsin at 37°C. Cells were dis-
sociated by trituration through a fire-polished Pasteur pipette.
After centrifugation at 250× g for 5 min, the resultant pellet was
washed twice in growth medium. Finally, cells were plated imme-
diately, either onto a six-well plate or glass cover-slips which
had previously been coated with poly l-ornithine (1µg/ml) and
laminin (25µg/ml) supplemented with murine nerve growth fac-
tor (100 ng/ml). After 24 h incubation, the culture medium was
supplemented with cytosine arabinoside (10µM) and incubated
for 12 h, after which time, culture medium was changed every
2 days until 70–80% confluence was reached.
IFNγ INJECTION INTO THE HYPOTHALAMIC ARC
Bilateral stereotaxic injections were performed as described (25).
Hundred nanograms of recombinant murine IFNγ (Peprotech)
was injected into the hippocampus of each hemisphere (two
injections per hemisphere: (1) caudal to bregma: −2.2 mm, lat-
eral: −2.5 mm, ventral: 2.4 mm; (2) caudal to bregma: −2.0 mm,
lateral:−2.0 mm, ventral: 1.6 mm). Twenty-four hours after injec-
tion, hippocampi of both hemispheres were isolated and used for
analysis.
STATISTICAL ANALYSIS
All data are represented as mean± SEM. Statistical analysis was
performed using the GraphPad Prism 6 software. p values were
calculated using an unpaired two-tailed Student’s t -test. p< 0.05
was considered significant.
RESULTS
Dkk3 DEFICIENCY DOES NOT INFLUENCE T-CELL DEVELOPMENT,
ACTIVATION, AND MEMORY FORMATION IN THE STEADY STATE
In order to identify the impact of Dkk3 on T cells of a poly-
clonal repertoire, we initially analyzed T-cell development in
Dkk3-deficient mice. Flow cytometric analysis revealed similar
percentages (Figure 1A) and numbers (Figure 1B) of thymocyte
subsets in Dkk3−/− and WT control mice. Additionally, cell sur-
face expression of CD69, which is a marker for the engagement
of the TCR-mediated positive selection process in the thymus,
was identical on the different thymocyte subsets in both strains
(Figure 1C). Frequencies of CD4+ CD25+ Foxp3+ regulatory T
cells in the thymus were not altered in Dkk3−/−mice (Figure 1D).
The ratio and numbers of CD4+ and CD8+ T cells in spleen
(Figures 1E,F) and peripheral lymph nodes (Figures 1G,H) were
also comparable. Moreover,analysis of TCR-Vβ expression showed
that genetic Dkk3 deletion did not strongly affect the development
of the TCR repertoire (Table 1). In addition to their developmen-
tal properties, we analyzed the activation and memory status of
T cells in naïve Dkk3−/− mice. Surface expression of the acti-
vation markers CD25 and CD69 on CD4+ as well as CD8+
T cells from spleen (Figure 1I) and lymph nodes (Figure 1K)
were comparable in Dkk3−/− and WT control mice. Similarly,
Dkk3 deficiency did not influence the expression of the mem-
ory markers CD44 and CD62L on CD4+ and CD8+ T cells in
spleen (Figure 1J) and lymph nodes (Figure 1L). Thus, these
results illustrate that Dkk3 does not interfere with T-cell devel-
opment, activation, and memory differentiation in the steady
state.
Dkk3 CONTRIBUTES TO THE ACCEPTANCE OF EMBRYOID BODY GRAFTS
Next, we were interested in the influence of Dkk3 on T-cell func-
tion under stimulatory conditions. As we previously identified
Dkk3 to be crucial for the establishment of peripheral CD8 T-
cell tolerance in a TCR transgenic system (20), we wondered
whether it may also influence CD8 T-cell responses in a poly-
clonal TCR repertoire. To address this question, we employed an
EBs transplantation model. EBs are embryonic stem cell-derived
composite tissues that have been previously reported to establish
an immunosuppressive micromilieu (22). In previous work, it has
been demonstrated that transplantation of male MHC class-I mis-
matched EBs under the kidney capsule of sex-matched recipient
mice results in 50% graft acceptance (22). Here, male CBK-derived
EBs were transplanted under the kidney capsule of male CBA
recipient mice. The accepted and rejected transplants were ana-
lyzed at day 28 for Dkk3 expression. Strikingly, Dkk3 protein was
detected in the accepted but not in the remains of the rejected
grafts (Figure 2A). To dissect the contribution of Dkk3 to the
establishment of the local immunosuppressive microenvironment
of the EB grafts, we administered anti-Dkk3 neutralizing or iso-
type control antibody following transplantation and assessed its
effect on graft survival. Interestingly, blocking of Dkk3 by the use
of the monoclonal antibody resulted in an increased incidence
graft rejection (Figure 2B). Taken together, our results demon-
strate that Dkk3 expression correlates with the development of a
local immunosuppressive micromilieu and the immunosuppres-
sive function of Dkk3 contributes to the acceptance of MHC class-I
mismatched EB grafts.
Dkk3−/− MICE SUFFER FROM EXACERBATED EXPERIMENTAL
AUTOIMMUNE ENCEPHALOMYELITIS
Dkk3 was reported to be strongly expressed in the brain (15).
Detailed immune-histological analysis revealed a highly specific
expression pattern within the organ. Prominent Dkk3 production
was restricted to the hippocampus, medulla, and the visual area of
the cerebral cortex (Figure 3A). Moreover, double-fluorescence
www.frontiersin.org February 2015 | Volume 6 | Article 78 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meister et al. Dickkopf-3 modulates local T-cell responses
FIGURE 1 | Dkk3 does not influenceT-cell development and activation in naïve Dkk3-deficient mice.
(Continued)
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FIGURE 1 | Continued
(A) Thymocytes from naïve Dkk3−/− mice and littermate controls were
stained for CD4 and CD8 and analyzed by flow cytometry. Distribution of
thymocyte subsets (DN: CD4− CD8− double negative; DP: CD4+ CD8+
double positive) is shown in a representative dot plot (left) and cumulative
data of percentages of whole thymocytes (right; n=4–5). (B) Absolute
numbers of respective thymocyte subsets from (A), determined by flow
cytometry (n=4–5). (C) Flow cytometric analysis of CD69 cell surface
expression on CD4+, CD8+, and CD4+ CD8+ double positive (DP) subsets
from (A). One representative histogram is shown (n= 4–5).
(D) Representative dot plot of CD25+ Foxp3+ cells among CD4 single
positive cells in the thymus of Dkk3−/− and WT control mice. (E) Analysis of
CD4+ and CD8+ T-cell subsets, among CD3 positive cells, in the spleen of
Dkk3−/− mice compared to littermate controls. One representative dot plot
(left) as well as respective cumulative data is shown. (F) Absolute numbers
of lymphocyte subsets from (D), determined by flow cytometry (n= 4–5).
(G) Analysis of CD4+ and CD8+ T-cell subsets among CD3 positive cells in
peripheral lymph nodes (LN) of Dkk3−/− mice and WT controls. One
representative dot plot (left) as well as respective cumulative data is shown.
(H) Absolute numbers of lymphocyte subsets from (F), determined by flow
cytometry (n=4–5). (I+K) Flow cytometric analysis of surface expression of
the activation markers CD25 and CD69 on CD4+ (upper row) and CD8+
(lower row) T cells in (I) spleen and (K) peripheral lymph nodes of naïve
Dkk3−/− (red) and WT control (black) mice. Shown is one representative
histogram (n=10). (J+L) Flow cytometric analysis of the surface expression
of CD44 and CD62L on CD4+ (upper row) and CD8+ (lower row) T cells in
(J) spleen and (L) peripheral lymph nodes of naïve Dkk3−/− and WT control
mice. Shown is one representative dot plot (n=8).
Table 1 | NormalT-cell repertoire in Dkk3-deficient mice.
THYMUS CD4
TCR-Vβ 2 3 4 5.1/5.2 6 7 8.1/8.2 9 10b 11 12 13 14 17a
WT 0.5 3.9 2.4 2.8 6.2 1.3 8.6 8.0 3.7 8.0 1.2 1.3 3.8 3.0
Dkk3−/− 0.5 4.5 4.3 2.8 4.6 1.1 10.6 6.8 5.1 6.8 0.7 1.0 3.3 3.3
THYMUS CD8
TCR-Vβ 2 3 4 5.1/5.2 6 7 8.1/8.2 9 10b 11 12 13 14 17a
WT 0.1 4.3 1.4 5.8 11.5 1.7 8.4 5.8 1.0 0.9 0.5 0.5 2.0 2.1
Dkk3−/− 0.1 5.5 3.3 4.6 9.5 1.6 9.5 6.1 1.6 1.2 0.2 0.2 2.5 1.6
SPLEEN CD4
TCR-Vβ 2 3 4 5.1/5.2 6 7 8.1/8.2 9 10b 11 12 13 14 17a
WT 0.6 4.9 2.6 2.3 3.1 1.0 7.5 8.7 0.6 3.5 0.7 1.0 3.6 2.5
Dkk3−/− 0.7 3.6 1.8 2.2 3.4 1.7 6.9 6.3 0.5 3.3 2.9 1.0 2.2 2.3
SPLEEN CD8
TCR-Vβ 2 3 4 5.1/5.2 6 7 8.1/8.2 9 10b 11 12 13 14 17a
WT 0.2 5.7 1.6 4.7 11.7 0.9 6.2 6.7 0.2 0.6 0.5 0.3 1.9 0.9
Dkk3−/− 0.3 4.2 0.7 5.2 8.0 0.6 5.5 4.3 1.1 0.9 1.5 0.6 1.1 0.5
Flow cytometric analysis of TCR-V β chain expression onT cells. Percentages of CD4 + or CD8 + T cells in thymus and spleen carrying the respective TCR-V β.
FIGURE 2 | Dkk3 protects MHC class-I mismatched transplanted
embryoid bodies from rejection. (A) Male CBK mice-derived embryoid
bodies were transplanted under the kidney capsule of male CBA mice.
Twenty-eight days after transplantation, remaining embryoid body tissue
was stained with anti-Dkk3 antibody. Shown is one representative
staining of accepted and remaining elements of the rejected tissue
(n=3). (B) Male CBK mice-derived embryoid bodies were transplanted
under the kidney capsule of male CBA mice. Seven days later, 1 mg
anti-Dkk3 or isotype control antibody was administered, followed by
0.5 mg every fourth day. Twenty-eight days after transplantation, the
acceptance rate of the transplants was determined (Log-rank test,
n=24, *p<0.05).
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FIGURE 3 | Dkk3 is expressed by neurons in distinct areas of the
brain. (A) Brain sections of C57BL6 mice were stained with anti-Dkk3
antibody. Brain regions were identified by morphology and location
(Scale bar: 25/50µm). (B) Respective brain sections from (A) were
stained with anti-Dkk3 (red) and either anti-neuronal nuclei (NeuN,
green, left panel) or anti-Glial fibrillary acidic protein (GFAP, green, right
panel) antibodies. Nuclei were counterstained with DAPI (Scale bar:
15/30µm).
staining indicated that neurons (NeuN+) but not astrocytes
(GFAP+) are the main source of Dkk3 in the brain (Figure 3B).
Based on our findings that Dkk3 in the microenvironment
might influence CD8 T-cell responses (Figure 2), we wondered
whether it acts on local CD4 T-cell reactivity as well. Due to the
locally high expression of Dkk3 in the brain, we chose the EAE
as a model system to answer this question. EAE is regarded as a
mouse-model of human multiple sclerosis, in which auto-reactive
CD4 T-cell-mediated demyelization is triggered in the CNS. Thus,
EAE was induced by immunization with a MOG33–55 peptide
and CFA in Dkk3−/− and WT mice and the disease course was
followed. The onset of EAE and the disease incidence were com-
parable in the two mouse groups (Figure 4A; Table 2). Moreover,
the severity of EAE in the acute phase was not significantly higher
after genetic deletion of Dkk3 (Figure 4A; Table 2). However,
Dkk3−/− mice failed to recover and exhibited a more chronic dis-
ease when compared to WT controls (Figure 4A). Most of the
EAE-affected WT mice recovered after initial paralysis and only
27.9% had clinical symptoms for longer than 20 days. In contrast,
the majority of diseased Dkk3−/−mice exhibited increased disease
duration, developing chronic disease or suffering from relapses, as
57.9% had clinical symptoms for longer than 20 days (Figure 4B).
We next sought to assess whether an established autoimmune
process is also susceptible to the effects of Dkk3. For this, we treated
mice 1 week after EAE induction with the neutralizing anti-Dkk3
antibody. Due to changes in the blood–brain barrier during EAE,
antibodies can access inflammatory lesions in the CNS (24). We
found that Dkk3 blockade starting 1 week after disease induc-
tion resulted in a significant increase and prolongation of EAE
symptoms, as compared to isotype-treated controls (Figure 4C)
suggesting that Dkk3 controls the potency and duration of the
T-cell effector phase, locally in the CNS.
To explore the consequences of Dkk3 deficiency on T-cell func-
tion in EAE more detailed, we analyzed the T-cell phenotype
in the CNS of diseased Dkk3−/− and WT control mice. While
IL-17- and GM-CSF-producing CD4+ T cells, have been shown
to play an important role in EAE induction (25, 26), IFNγ was
reported to have a pleiotropic effect in EAE. Depending on the
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FIGURE 4 | Dkk3-deficient mice suffer from prolonged and
exacerbated EAE. (A) Dkk3−/− and WT mice were immunized s.c. with
MOG33–55 peptide in CFA. The mean EAE scores of one representative out
of three experiments are shown (n=9). (B) The percentage of living mice
with disease duration longer than 20 days was determined. Results from
two independent experiments were pooled (n=16, *p<0.05).
(C) C57BL6 mice received either anti-Dkk3 or isotype control antibody at
days 7 (1 mg/mouse), 10, 13, 16, 21 (0.5 mg/mouse) after MOG33–55/CFA
immunization. Shown is one representative experiment out of three
(n=10, *p<0.05).
Table 2 | Onset and severity in the acute phase of experimental
autoimmune encephalomyelitis in Dkk3-deficient mice was
comparable to WT controls.
Incidence % Day of disease
onset
Mean maximal
disease severity
Dead
mice
WT 24/26 92.3 11.1±2.6 2.4±1.1 1
Dkk3−/− 25/25 100 10.8±2.3 3.1±1.1 4
cell type of origin and time point of expression, it may medi-
ate disease-promoting or disease-limiting effects (27). Therefore,
we re-stimulated lymphocytes isolated from the CNS with MOG
peptide and assessed the numbers of IL-17, GM-CSF, and IFNγ-
producing CD4 T cells. Since the MOG33–55 peptide also contains
a CD8-epitope able to induce IFNγ production and EAE (28),
we also analyzed CD8+ IFNγ+ T cells. The presence of CD4+
CD25+ Foxp3+ regulatory T cells, which are shown to be potent
down-modulators of the T-cell response in EAE (29), was also
determined.
At the peak of the disease, when EAE symptoms in Dkk3−/−
and WT mice were still comparable (Figure 5A), the numbers
of infiltrating CD4+ and CD8+ T cells in the CNS were simi-
lar (Figure 5B). However, while GM-CSF and IFNγ producing
cells were not affected (Figures 5E–G), the proportion of IL-17-
producing CD4+ T cells was slightly increased in the CNS of
Dkk3-deficient mice (Figure 5D). Interestingly, at the same time,
the proportion of CD4+ CD25+ Foxp3+ regulatory T cells was
significantly elevated (Figure 5C). These differences were absent
in spleen and draining lymph nodes (Figures 5H–J) indicating a
local effect of Dkk3.
In contrast, during the recovery phase of the disease, when
more severe EAE symptoms in Dkk3−/− mice were manifest
(Figure 6A), we found higher numbers of CD4+ and CD8+ T
cells in the CNS but not in the draining lymph nodes (Figure 6H)
of Dkk3-deficient mice compared to WT controls (Figure 6B).
Furthermore, the ratio of IFNγ-producing CD4+ and CD8+ was
significantly increased (Figures 6F,G) while the proportion of IL-
17 and GM-CSF-producing CD4+ T cells (Figures 6D,E) as well
as CD4+ CD25+ Foxp3+ cells (Figure 6C) was similar in the CNS
of both strains. The impact on the T-cell phenotype was again a
brain-specific effect, since Dkk3 deficiency did not interfere with
the levels of IFNγ-producing CD4+ and CD8+ T cells in spleen
and draining lymph nodes (Figure 6I). Thus, our data indicate
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FIGURE 5 | Increased proportions of CD4+ CD25+ Foxp3+ regulatoryT
cells and IL-17-producing CD4+ T cells in the CNS but not in the
draining lymph nodes (Figure 6H) of Dkk3−/− at the peak of EAE.
(A) EAE was induced in Dkk3−/− and WT mice by immunization with
MOG33–55 in CFA. Mean clinical EAE score over time is displayed. At the
indicated time point (black arrow, 14 days after EAE induction), half of the
mice were sacrificed and lymphocytes were isolated from brain and
spinal cord for analysis in (B–G) (n=8). (B) Percentages of CD4+ and
CD8+ T cells among leukocytes in the CNS of Dkk3−/− and WT mice.
(C) Proportion of CD25+ Foxp3+ of CD4+ cells (*p<0.05). (D–G) Isolated
lymphocytes from (A) were re-stimulated in vitro with 50µg/ml MOG33–55
peptide for 6 h in the presence of Golgi Plug and intracellularly stained for
the respective cytokines. Shown is one representative dot plot (left panel)
and cumulative data of three individual experiments (n= 8).
(D) Percentages of IL-17+ of CD4+ T cells (*p<0.05). (E) Percentages of
GM-CSF+ of CD4+ T cells. (F) Percentages of IFNγ+ of CD4+ T cells.
(G) Percentages of IFNγ+ of CD8+ T cells. (H) Percentages of CD4+ and
CD8+ T cells in spleen and peripheral lymph nodes (LN) of respective
mice from (A). (I) Percentages of CD25+ Foxp3+ of CD4+ cells in spleen
and draining lymph nodes (LN) of respective mice from (A).
(J) Percentages of IL-17+ of CD4+ cells in spleen and draining lymph
nodes (LN) of respective mice from (A).
that Dkk3 modulates T-cell activation and polarization during
the advanced phase of EAE locally in the CNS and consequently
promotes symptom recovery.
Dkk3 SERVES AS PART OF AN IFNγ NEGATIVE FEEDBACK LOOP IN THE
BRAIN DURING EAE
IFNγ plays a multifaceted role in EAE. Its disease-limiting effect
was suggested to be partially mediated by the induction of anti-
inflammatory mediators like IDO (14) or nitric oxide (NO) (30).
Despite elevated IFNγ levels in the CNS, we observed a pro-
longed disease process in the Dkk3-deficient situation. Therefore,
we hypothesized that Dkk3 might be part of an IFNγ-mediated
regulatory mechanism, that is lost in Dkk3−/− mice. In order
to test this, we initially analyzed the capacity of IFNγ to induce
Dkk3 expression during EAE in the brain. Comparison of Dkk3
expression in the brain of healthy controls and EAE-bearing mice,
at the peak of diseases, revealed a significant increase of Dkk3 lev-
els in the inflamed brains of WT mice. However, such an elevation
was not detectable in brains of IFNγR1−/−mice (Figure 7A), indi-
cating an IFNγ-dependent induction of Dkk3 expression in EAE
brains. In order to find out whether IFNγ is able to up-regulate
Dkk3 expression in neuronal cells, we made use of ex vivo cultured
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FIGURE 6 | Increased numbers of IFNγ-producingT cells in the CNS of
EAE diseased Dkk3−/− mice in the recovery phase. (A) EAE was induced in
Dkk3−/− and WT mice by immunization with MOG33–55 in CFA. Mean clinical
EAE score over time is displayed. At the indicated time point (black arrow,
20 days after EAE induction), mice were sacrificed and lymphocytes were
isolated from brain and spinal cord for analysis in (B–G). (B) Percentages of
CD4+ and CD8+ T cells among leukocytes in the CNS of Dkk3−/− and WT mice
(*p<0.05). (C) Proportion of CD25+ Foxp3+ of CD4+ cells. (D–G) Isolated
lymphocytes from (A) were re-stimulated in vitro with 50µg/ml MOG33–55
peptide for 6 h in the presence of Golgi Plug and intracellularly stained for the
respective cytokines. Shown is one representative dot plot (left panel) and
cumulative data of three individual experiments (n= 8). (D) Percentages of
IL-17+ of CD4+ T cells. (E) Percentages of GM-CSF+ of CD4+ T cells. (F)
Percentages of IFNγ+ of CD4+ T cells (*p< 0.05). (G) Percentages of IFNγ+ of
CD8+ T cells (*p<0.05). (H) Percentages of CD4+ and CD8+ T cells in spleen
and draining lymph nodes (LN) of respective mice from (A). (I) Percentages of
IFNγ+ of CD4+ and CD8+ cells in spleen and draining lymph nodes (LN) of
respective mice from (A).
primary DRG neurons. Histological analysis revealed, just as for
neurons in vivo, that these cells express Dkk3 (Figure 7B). More-
over, IFNγ stimulation of DRGs increased the basal expression
level (Figure 7C) and secretion of Dkk3 protein (Figure 7D) by
nearly sixfold. As expected, this up-regulation was not observed in
IFNγR1−/− control DRGs (Figure 7E). Thus, IFNγ up-regulates
Dkk3 expression in neuronal cells.
In order to find out whether Dkk3 is, in turn, capable of influ-
encing IFNγ activity during EAE, we analyzed IFNγ-induced gene
expression in the brain. To enhance the pathological situation,
in which the first IFNγ-producing T cells enter the brain 7 days
after EAE induction (31), we performed the following experiment:
7 days after EAE induction in Dkk3−/− and WT mice, IFNγ was
stereotactically injected into the hippocampal arc of the mice, and
expression of IFNγ target genes was analyzed 24 h after adminis-
tration. This area was targeted because of the high local concen-
tration of Dkk3 in the hippocampus (Figure 3A). As a control,
hippocampi of non-injected animals were analyzed. QRT-PCR
analysis revealed that IFNγ injection strongly induced IFNγ tar-
get gene expression in hippocampi of injected mice compared
to non-injected controls. Furthermore, this induction was more
prominent in Dkk3-deficient mice. In Dkk3−/− hippocampi, the
expression of Gbp2 and Cxcl10 was significantly enhanced upon
IFNγ administration. However, Cxcl9, Ccl2, and Ccl5 expression
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FIGURE 7 | Neuronal Dkk3 expression is induced by IFNγ and limits IFNγ
induced gene expression in the brain. (A) Dkk3 protein levels in brain
lysates of healthy and EAE-diseased WT and IFNγR1−/− mice were measured
by ELISA. EAE was induced by immunization with MOG/CFA and minimal
clinical EAE score of used mice was 4. Protein amount was related to organ
weight (n=5, **p< 0.01). (B) Histological analysis of ex vivo cultured,
primary dorsal route ganglia (DRG) stained with anti-Dkk3 (upper row) or
isotype control antibody (lower row). (C) QRT-PCR data showing relative Dkk3
expression in cells from (C) (n=3, **p<0.01). (D) Dkk3 ELISA of supernatant
from control and IFNγ stimulated primary DRG isolated from WT mice. DRG
were stimulated for 24 h with 100 ng/ml IFNγ (n= 3, **p< 0.01). (E) QRT-PCR
data showing relative Dkk3 expression in control and IFNγ stimulated primary
DRG from IFNγR1−/− mice. DRG were stimulated for 24 h with 100 ng/ml IFNγ
(n=3). (F) WT and Dkk3−/− were immunized with MOG33–55 in CFA. Seven
days later, 100 ng recombinant IFNγ in PBS was injected stereotactically into
hippocampi of the respective mice. One day later, hippocampi were harvested
and RNA was isolated. As controls, hippocampi of non-IFNγ-injected mice,
8 days after MOG/CFA immunization were used. Shown are qRT-PCR data of
the relative expression of Gbp2, Cxcl10, Cxcl9, Ccl2 (MCP-1), Ccl5 (RANTES)
in respective hippocampi (n=8, *p<0.05, **p<0.01).
was not much altered (Figure 7F). In control hippocampi, dkk3
deficiency did not cause an increase in IFNγ target gene expression
(Figure 7F). In summary, these data suggest that Dkk3 negatively
modulates IFNγ activity in the EAE brain.
DISCUSSION
Regulation of T-cell responses within tissues is essential for the
preservation of organ integrity and function. In this context, the
tissue microenvironment plays a pivotal role in the establishment
of an immunological balance. In this study, we provide evidence
that the secreted glycoprotein Dkk3 functions as a tissue-derived
modulator of local T-cell responses. Our data show that Dkk3
(i) is part of the local microenvironment that protects trans-
planted MHC class-I mismatched embryo bodies from CD8+
T-cell-dependent rejection and (ii) contributes to the control of
CD4+ T-cell-mediated autoimmune encephalomyelitis by limita-
tion of T-cell activation and polarization as well as IFNγ activity
in the CNS.
Our group previously demonstrated that the presence of Dkk3
is essential for the establishment of peripheral CD8+ T-cell tol-
erance in a TCR/MHC class-I double transgenic mouse system.
Genetic deletion or antibody blockade of Dkk3 in this system
led to an increased local CD8+ T-cell reactivity resulting in
an enhanced, antigen-specific eradication of tumors and skin
grafts (20). The investigations performed here display a similar,
immune-modulatory role of Dkk3 for the polyclonal T-cell reper-
toire in vivo. Transplanted EBs were shown to create an immune
suppressive microenvironment by, for example, the release of
transforming growth factor-β (TGF-β) (22). EB transplants were
shown to express Dkk3 and antibody-mediated blockade of Dkk3
increased the frequency of their rejection, albeit some EB grafts
remaining intact. We therefore, suggest that Dkk3 represents one
constituent of the local, suppressive EB micromilieu suppressing
cytotoxic CD8+ T-cell responses. This view is supported by the
observation that the global absence of Dkk3 did not lead to a sys-
temic hyperresponsiveness of cytotoxic CD8+ T cells in vivo in the
polyclonal repertoire (20).
In contrast to the double transgenic system in which Dkk3
was expressed by a unique, tolerant CD8+ T-cell population, (20),
Dkk3 was reported to be mainly produced by tissue cells but
very rarely in the hematopoietic compartment in the physiolog-
ical situation. Dkk3 expression in the hematopoietic system was
only detected at a transcriptional level in a CD27 negative, IL-
17-producing subset of γδ T cells (32) and long-term memory
CD8 T cells (33) but not in naïve or activated conventional αβ
T cells. Highest Dkk3 levels were found in organs like uterus,
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placenta, eye, and brain (15, 17). These organs are classically
considered to be immune-privileged, a situation in which the tis-
sue is protected from otherwise damaging immune responses.
This is of particular importance as their regenerative capacity
is very low and cellular damage would strongly impair organ
integrity and function (34, 35). Based on the immune suppres-
sive capacity of Dkk3 shown here, one could speculate that Dkk3
is one contributor to the creation of such immunosuppressive
microenvironments.
Indeed, our studies on EAE demonstrate an important role of
Dkk3 in the regulation of CD4+ T-cell responses. Dkk3 deficiency
resulted in a delayed EAE remission with exacerbated symptoms
during recovery phase but did not lead to higher EAE susceptibil-
ity, premature disease onset nor increased severity at the peak of
disease. These data indicate that Dkk3 mediates its function rather
locally during the T-cell effector phase, rather than systemically
in spleen and lymph nodes during the T-cell priming phase. This
assumption is supported by the finding that blockade of Dkk3
by a monoclonal antibody, starting 7 days after immunization, is
sufficient to induce a similar phenotype. The locally restricted
function might also explain, at least in part, why Dkk3 deficiency
does not lead to T-cell activation in secondary lymphoid organs in
the steady state and thus, why Dkk3−/− mice do not suffer from
spontaneous autoimmunity (21).
The observed shift of T-cell polarization within the CNS of
EAE-bearing Dkk3-deficient mice varied at different stages of the
disease. At the peak of disease, a higher proportion of Th17 and
Foxp3+ regulatory T cells was detected. While Th17 cells are cru-
cial for the induction of EAE (25, 26), Foxp3+ Tregs were shown
to suppress encephalitogenic T-cell reactivity (29). As both sub-
sets were enriched in the Dkk3−/− CNS, it could be that they
compensate each others function, resulting in a similar EAE score
compared to WT mice. However, in the recovery phase, the height-
ened EAE severity in Dkk3-deficient mice was accompanied by
elevated T-cell numbers and an increase in IFNγ producing CD4+
and CD8+ T cells in the CNS. Again, the altered T-cell polariza-
tion in the CNS of Dkk3-deficient mice upon EAE induction was
restricted to the brain and not observed in the secondary lymphoid
organs endorsing the hypothesis of local Dkk3 action.
IFNγ has a multifaceted role in EAE. On the one hand, it has
been positively correlated with disease severity (36), while on the
other hand genetic or antibody-mediated neutralization exhib-
ited disease-ameliorating effects (37–39). It was suggested that,
after being pro-inflammatory and disease-promoting in the early
phase, IFNγ exerts an anti-inflammatory, beneficial function in
the later phases (27). Its disease-providing properties are mediated
by induction of antigen presentation, promotion of Th1 differen-
tiation as well as up-regulation of adhesion molecules and the
induction of a wide range of pro-inflammatory mediators (40).
The anti-inflammatory function is attributed to the inhibition of
T-cell expansion, induction of Foxp3 positive regulatory cells, and
the up-regulation of anti-inflammatory mediators like IDO or the
inducible nitric oxide synthase (iNOS) (27, 30, 41). Our studies
reveal that Dkk3 expression is up-regulated in the brain of EAE-
bearing mice in an IFNγ-dependent manner. Moreover, we found
that Dkk3 is able to regulate the expression of certain IFNγ target
genes in the brain. Together these results suggest that neuron-
derived Dkk3 might serve as a mediator of the anti-inflammatory
arm of IFNγ during EAE, conducting its function by regulation of
IFNγ activity in a negative feedback mechanism.
The immune modulator IDO also locally suppresses T-
cell responses by the catabolic deprivation of tryptophan and
production of kynurenine metabolites, and is thus, thought to
play an important role in the induction of immune tolerance and
the prevention of autoimmunity (42, 43). It is expressed in the
brain and is further up-regulated by IFNγ. Chemical inhibition
or genetic deletion of IDO causes exacerbated EAE symptoms
(14, 44). Moreover, IDO deficiency leads to increased numbers
of IFNγ-producing T cells in EAE-bearing mice and treatment
of transferred EAE with kynurenines shifts the cellular immune
response from Th1 to Th2 (45). These results led to the assump-
tion that IDO expression in the CNS initiates a negative feedback
loop to self-limit autoimmunity (44). In addition, via the inter-
action with its ligand PD-1, tissue-derived PD-L1 is important
for the establishment of peripheral tolerance. In a fully MHC
mismatched cardiac allograft model, blockade of PD-L1 abro-
gated CTLA4Ig-induced tolerance and accelerated organ rejection.
This was associated with an increase in the frequency of IFNγ-
producing allo-reactive T cells and expansion of CD8 effector cells
(46). High PD-L1expression was shown to be key for maintain-
ing immune privilege in the eye (47) and feto-maternal tolerance
in the placenta (48). PD-L1-deficient mice do not display T-cell
activation per se or spontaneous autoimmunity in the steady state.
However, upon MOG immunization, these mice suffer from exac-
erbated EAE (49). The functional characteristics of Dkk3 identi-
fied here seem quite similar to those of these well-characterized
immune-modulatory molecules.
Mechanistically, Dkk3 does not conduct its function via inter-
ference with the development of the TCR repertoire. This is
indicated by the findings that the TCR-Vβ frequencies are not dis-
similar, that antibody blockade reflects the phenotype of genetic
deletion, and that immune responses in the lymphoid compart-
ments are not influenced by Dkk3 (20). Our finding that Dkk3
interferes with the expression of IFNγ target genes like Gbp2
or Cxcl10 suggests that Dkk3 may not necessarily act directly
on T cells but may also affect the function of ambient cells in
the microenvironment which in turn modulate T-cell responses.
For example, oligodendrocytes and astrocytes were shown to up-
regulate the expression of Gbp2 and Cxcl10 in response to IFNγ
during EAE (50, 51). Since Dkk3 may act as Wnt pathway modu-
lator (17–19), it is possible that its immune-modulatory function
also relies on this property, especially as Wnt signaling is known to
influence T-cell effector function (52) and linage commitment
(53–55). However, the distinct cellular and molecular mecha-
nisms through which Dkk3 mediates its function warrant further
investigation.
In summary, our results strongly suggest that Dkk3 contributes
to the establishment of peripheral T-cell tolerance and the pro-
tection of tissues from self-destructive immune responses. These
findings suggest that Dkk3 should be considered as a poten-
tial target for therapeutic approaches in transplant rejection and
autoimmunity.
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